Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (CytoSorb<sup>®</sup>) in patients with sepsis and septic shock
Rajib Paul, Prachee Sathe, Senthil Kumar, Shiva Prasad, M. A. Aleem, Prashant Sakhalvalkar
Abstract
BACKGROUND: therapy is a new technology that helps to address the cytokine storm and to regain control over various inflammatory conditions. AIM: therapy used as an adjunctive therapy along with standard of care in septic patients admitted to intensive care unit (ICU). METHODS: value < 0.05 was considered to be statistically significant. RESULTS: therapy was safe and well tolerated with no adverse events reported. CONCLUSION: might be an effective adjuvant therapy in stabilizing sepsis and septic shock patients. However, it is advisable to start the therapy at an early stage (preferably within 24 h after onset of septic shock).
Topics & Concepts
Septic shockMedicineExtracorporealSepsisCytokineProspective cohort studySevere sepsisIntensive care medicineInternal medicineSepsis Diagnosis and TreatmentMechanical Circulatory Support DevicesIntensive Care Unit Cognitive Disorders